Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00650377 | Fed Study of Finasteride Tablets 5 mg and Proscar® Tablets 5 mg | PHASE1 | COMPLETED | 30 | — | — | Oct 1, 2004 | Oct 1, 2004 | Apr 23, 2024 | 1 | United States |
| NCT00648791 | Fasting Study of Finasteride Tablets 5 mg and Proscar Tablets 5 mg | PHASE1 | COMPLETED | 29 | — | — | Sep 1, 2004 | Oct 1, 2004 | Apr 24, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Finasteride Tablets 5 mg |
| 2 | ACTIVE_COMPARATOR | Proscar® Tablets 5 mg |
| Name | Type | Description |
|---|---|---|
| Finasteride Tablets 5 mg | DRUG | 5mg, single dose fed |
| Proscar® Tablets 5 mg | DRUG | 5mg, single dose fed |
| Proscar Tablets 5 mg | DRUG | 5mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older 2. Sex: Male During the course of the study, from study screen until study exit, male volunteers must use a spermicide-containing barrier method of contraception to prevent the pregnancy of their sexual partner. This advice should be documented in the ...